Are we not attempting to do the same thing with our add-on partners IMAGION Biosystems?
From ASTRAZENECA
We are working hard to continually advance what we know about the role of DDR in cancer and drive the development of targeted DDR therapies to enable precision medicine. To achieve this, we need to be able to identify and test which patients have genetic biomarkers indicating underlying DDR defects, to allow patients to be matched to the right treatment.
Ann: Section 708A Cleansing Statement, page-17
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $19.49K | 2.78M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1514113 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1874624 | 9 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |